Medication Review: What is the clinical profile of Resmetirom, including dosing schedules?
GHAPPcast3 Okt 2024

Medication Review: What is the clinical profile of Resmetirom, including dosing schedules?

Thank you to Madrigal for your support of this Medication Review Video Module.

In this Medication Review Video Module, Whitney Steinmetz, NP, provides an in-depth discussion on the clinical profile of Retam (Resd) for Metabolic-Associated Steatohepatitis (MASH) with moderate to advanced F2 or F3 fibrosis. While Retam is not currently FDA-approved for patients with cirrhosis, ongoing trials are evaluating its potential in this population.

As a partial agonist of the thyroid hormone receptor beta, Retam targets hepatic metabolism, reducing intrahepatic triglycerides and improving liver health without significantly affecting thyroid hormone receptor alpha—which mediates effects on the heart and bones. The 52-week study demonstrated its effectiveness in resolving steatohepatitis and improving fibrosis without worsening inflammation.

Available in 60 mg, 80 mg, and 100 mg tablets, dosage is weight-based, with 80 mg recommended for patients under 100 kg and 100 mg for those over 100 kg. Due to its metabolism via CYP2C8, Retam should not be used with strong inhibitors like gemfibrozil, and statin doses may require adjustment.

Common side effects include nausea and diarrhea, which typically resolve over time. Mild serum aminotransferase elevations may occur early in treatment but often decrease within 3-6 months, correlating with reductions in hepatic fat and steatohepatitis.

For more expert insights on MASH management, visit the GHAPP website or the GHAPP ACE app.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(161)

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Aug 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Aug 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Aug 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Juli 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Juni 17min

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC,...

9 Juni 12min

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Juni 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Maj 3min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-beroende-medberoende
rss-jossan-nina
bullfika
rss-vuxna-pa-latsas
inga-beiga-morsor
not-fanny-anymore
johannes-hansen-podcast
angestpodden
sexnoveller-deluxe
sova-med-dan-horning
rss-viktmedicinpodden
rss-hos-psykologen
halsoveckan-by-tyngre
sa-in-i-sjalen
rss-traningsklubben
hacka-livet
tyngre-radio
rss-angra-inget-3
rss-basta-livet